[KSCI] Korea Science Citation Index Service

http://dx.doi.org/10.4110/in.2015.15.2.51

Recent Advances of Vaccine Adjuvants for Infectious Diseases

Lee, Sujin (Department of Pediatrics, Emory University, School of Medicine)
Nguyen, Minh Trang (Department of Pediatrics, Emory University, School of Medicine)

Publication Information

IMMUNE NETWORK / v.15, no.2, 2015 , pp. 51-57 More about this Journal

Abstract

Vaccines are the most effective and cost-efficient method for preventing diseases caused by infectious pathogens. Despite the great success of vaccines, development of safe and strong vaccines is still required for emerging new pathogens, re-emerging old pathogens, and in order to improve the inadequate protection conferred by existing vaccines. One of the most important strategies for the development of effective new vaccines is the selection and usage of a suitable adjuvant. Immunologic adjuvants are essential for enhancing vaccine potency by improvement of the humoral and/or cell-mediated immune response to vaccine antigens. Thus, formulation of vaccines with appropriate adjuvants is an attractive approach towards eliciting protective and long-lasting immunity in humans. However, only a limited number of adjuvants is licensed for human vaccines due to concerns about safety and toxicity. We summarize current knowledge about the potential benefits of adjuvants, the characteristics of adjuvants and the mechanisms of adjuvants in human vaccines. Adjuvants have diverse modes of action and should be selected for use on the basis of the type of immune response that is desired for a particular vaccine. Better understanding of current adjuvants will help exploring new adjuvant formulations and facilitate rational design of vaccines against infectious diseases.

Keywords

Vaccine; Adjuvant; Infectious disease; Innate immunity; Adaptive immunity;

Citations & Related Records

Times Cited By KSCI : 1 (Citation Analysis)

Reference
Cited By KSCI

1	Descamps, D., K. Hardt, B. Spiessens, P. Izurieta, T. Verstraeten, T. Breuer, and G. Dubin. 2009. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum. Vaccin. 5: 332-340. DOI
2	Beran, J. 2008. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin. Biol. Ther. 8: 235-247. DOI
3	Didierlaurent, A. M., S. Morel, L. Lockman, S. L. Giannini, M. Bisteau, H. Carlsen, A. Kielland, O. Vosters, N. Vanderheyde, F. Schiavetti, D. Larocque, M. M. Van, and N. Garcon. 2009. AS04, an aluminum salt- and TLR4 agonist- based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183: 6186-6197. DOI
4	Krieg, A. M. 2006. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5: 471-484. DOI
5	Eng, N. F., N. Bhardwaj, R. Mulligan, and F. az-Mitoma. 2013. The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV review. Hum. Vaccin. Immunother. 9: 1661-1672. DOI
6	Hasegawa, H., T. Ichinohe, A. Ainai, S. Tamura, and T. Kurata. 2009. Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses. Ther. Clin. Risk Manag. 5: 125-132.
7	Duthie, M. S., H. P. Windish, C. B. Fox, and S. G. Reed. 2011. Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev. 239: 178-196. DOI
8	Turley, C. B., R. E. Rupp, C. Johnson, D. N. Taylor, J. Wolfson, L. Tussey, U. Kavita, L. Stanberry, and A. Shaw. 2011. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29: 5145-5152. DOI
9	Morein, B., B. Sundquist, S. Hoglund, K. Dalsgaard, and A. Osterhaus. 1984. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308: 457-460. DOI
10	Garcia, A., and J. B. De Sanctis. 2014. An overview of adjuvant formulations and delivery systems. APMIS 122: 257-267. DOI
11	Cummings, J. F., M. D. Spring, R. J. Schwenk, C. F. Ockenhouse, K. E. Kester, M. E. Polhemus, D. S. Walsh, I. K. Yoon, C. Prosperi, L. Y. Juompan, D. E. Lanar, U. Krzych, B. T. Hall, L. A. Ware, V. A. Stewart, J. Williams, M. Dowler, R. K. Nielsen, C. J. Hillier, B. K. Giersing, F. Dubovsky, E. Malkin, K. Tucker, M. C. Dubois, J. D. Cohen, W. R. Ballou, and D. G. Heppner, Jr. 2010. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 $CD4^+$ T cells but does not protect against experimental Plasmodium falciparum infection. Vaccine 28: 5135-5144. DOI
12	De, G. E., E. Tritto, and R. Rappuoli. 2008. Alum adjuvanticity: unraveling a century old mystery. Eur. J. Immunol. 38: 2068-2071. DOI
13	O'Hagan, D. T., G. S. Ott, and N. G. Van. 1997. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol. Med. Today 3: 69-75. DOI
14	Garcon, N., D. W. Vaughn, and A. M. Didierlaurent. 2012. Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Rev. Vaccines 11: 349-366. DOI
15	Atmar, R. L., and W. A. Keitel. 2009. Adjuvants for pandemic influenza vaccines. Curr. Top. Microbiol. Immunol. 333: 323-344.
16	Schwendener, R. A. 2014. Liposomes as vaccine delivery systems: a review of the recent advances. Ther. Adv. Vaccines 2: 159-182. DOI
17	Leroux-Roels, G. 2010. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28 Suppl 3: C25-C36. DOI
18	Moser, C., M. Muller, M. D. Kaeser, U. Weydemann, and M. Amacker. 2013. Influenza virosomes as vaccine adjuvant and carrier system. Expert Rev. Vaccines 12: 779-791. DOI
19	Garcon, N., M. Wettendorff, and M. M. Van. 2011. Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile. Expert Opin. Biol. Ther. 11: 667-677. DOI
20	Fauci, A. S. 2001. Infectious diseases: considerations for the 21st century. Clin. Infect. Dis. 32: 675-685. DOI
21	WHO Ebola Response Team. 2014. Ebola virus disease in West Africa--the first 9 months of the epidemic and forward projections. N. Engl. J. Med. 371: 1481-1495. DOI
22	Riese, P., K. Schulze, T. Ebensen, B. Prochnow, and C. A. Guzman. 2013. Vaccine adjuvants: key tools for innovative vaccine design. Curr. Top. Med. Chem. 13: 2562-2580. DOI
23	Baxter D. 2007. Active and passive immunity, vaccine types, excipients and licensing. Occup. Med. (Lond). 57: 552-556. DOI
24	Reed, S. G., M. T. Orr, and C. B. Fox. 2013. Key roles of adjuvants in modern vaccines. Nat. Med. 19: 1597-1608. DOI
25	Glenny, A. T., C. G. Pope, H. Waddington, and U. Wallace. 1926. Immunological notes. XVII-XXIV. J. Pathol. Bacteriol. 29: 31-40. DOI
26	Brewer, J. M. 2006. (How) do aluminium adjuvants work?. Immunol. Lett. 102: 10-15. DOI
27	Lindblad, E. B. 2004. Aluminium adjuvants--in retrospect and prospect. Vaccine 22: 3658-3668. DOI
28	Awate, S., L. A. Babiuk, and G. Mutwiri. 2013. Mechanisms of action of adjuvants. Front. Immunol. 4: 114.
29	Glenny, A. T., and C. G. Pope. 1925. The antigenic effect of intravenous injection of diphtheria toxin. J. Pathol. Bacteriol. 28: 273-278. DOI
30	Hutchison, S., R. A. Benson, V. B. Gibson, A. H. Pollock, P. Garside, and J. M. Brewer. 2012. Antigen depot is not required for alum adjuvanticity. FASEB J. 26: 1272-1279. DOI
31	Marrack, P., A. S. McKee, and M. W. Munks. 2009. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol. 9: 287-293. DOI
32	Reed, S. G., S. Bertholet, R. N. Coler, and M. Friede. 2009. New horizons in adjuvants for vaccine development. Trends Immunol. 30: 23-32. DOI
33	Gupta, R. K. 1998. Aluminum compounds as vaccine adjuvants. Adv. Drug Deliv. Rev. 32: 155-172. DOI
34	O'Hagan, D. T., G. S. Ott, E. De Gregorio, and A. Seubert. 2012. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 30: 4341-4348. DOI
35	Podda, A. 2001. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19: 2673-2680. DOI
36	Gasparini, R., F. Schioppa, M. Lattanzi, M. Barone, D. Casula, M. Pellegrini, K. Veitch, and N. Gaitatzis. 2010. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects. Int. J. Clin. Pract. 64: 432-438. DOI
37	O'Hagan, D. T., G. S. Ott, G. V. Nest, R. Rappuoli, and G. D. Giudice. 2013. The history of MF59( $^{(R)}$ ) adjuvant: a phoenix that arose from the ashes. Expert Rev. Vaccines 12: 13-30. DOI
38	Almeida, J. D., D. C. Edwards, C. M. Brand, and T. D. Heath. 1975. Formation of virosomes from influenza subunits and liposomes. Lancet 2: 899-901.
39	Morel, S., A. Didierlaurent, P. Bourguignon, S. Delhaye, B. Baras, V. Jacob, C. Planty, A. Elouahabi, P. Harvengt, H. Carlsen, A. Kielland, P. Chomez, N. Garcon, and M. M. Van. 2011. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29: 2461-2473. DOI
40	Brito, L. A., and D. T. O'Hagan. 2014. Designing and building the next generation of improved vaccine adjuvants. J. Control Release 190: 563-579. DOI
41	Moser, C., M. Amacker, A. R. Kammer, S. Rasi, N. Westerfeld, and R. Zurbriggen. 2007. Influenza virosomes as a combined vaccine carrier and adjuvant system for prophylactic and therapeutic immunizations. Expert Rev. Vaccines 6: 711-721. DOI
42	Cusi, M. G. 2006. Applications of influenza virosomes as a delivery system. Hum. Vaccin. 2: 1-7. DOI
43	Medzhitov, R. 2001. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1: 135-145. DOI
44	Coffman, R. L., A. Sher, and R. A. Seder. 2010. Vaccine adjuvants: putting innate immunity to work. Immunity 33: 492-503. DOI
45	Gustafson, G. L., and M. J. Rhodes. 1992. Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. Res. Immunol. 143: 483-488. DOI
46	Garcon, N., P. Chomez, and M. M. Van. 2007. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6: 723-739. DOI
47	Calabro, S., M. Tortoli, B. C. Baudner, A. Pacitto, M. Cortese, D. T. O'Hagan, G. E. De, A. Seubert, and A. Wack. 2011. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29: 1812-1823. DOI
48	Taylor, D. N., J. J. Treanor, E. A. Sheldon, C. Johnson, S. Umlauf, L. Song, U. Kavita, G. Liu, L. Tussey, K. Ozer, T. Hofstaetter, and A. Shaw. 2012. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 30: 5761-5769. DOI
49	Oleszycka, E., and E. C. Lavelle. 2014. Immunomodulatory properties of the vaccine adjuvant alum. Curr. Opin. Immunol. 28: 1-5. DOI
50	Chan, E. H., T. F. Brewer, L. C. Madoff, M. P. Pollack, A. L. Sonricker, M. Keller, C. C. Freifeld, M. Blench, A. Mawudeku, and J. S. Brownstein. 2010. Global capacity for emerging infectious disease detection. Proc. Natl. Acad. Sci. U. S. A. 107: 21701-21706. DOI
51	Lovgren, B. K., B. Morein, and A. D. Osterhaus. 2011. ISCOM technology-based Matrix $M^{TM}$ adjuvant: success in future vaccines relies on formulation. Expert Rev. Vaccines 10: 401-403. DOI

None	(2015) F1000Research Blood Interferon Signatures Putatively Link Lack of Protection Conferred by the RTS,S Recombinant Malaria Vaccine to an Antigen-specific IgE Response / 4 (None) , 919
4	(2015) Natural products chemistry & research QS-21: A Potent Vaccine Adjuvant / 3 (4) , e113
9	(2015) Future virology Communicate, educate: tackling misconceptions to boost vaccine uptake / 10 (9) , 1029
1	(2016) Network modeling analysis in health informatics and bioinformatics In silico designing of some agonists of toll-like receptor 5 as a novel vaccine adjuvant candidates / 5 (1) , None
6	(2016) Russian journal of marine biology Prospects for the use of sulfated polysaccharides from brown seaweeds as vaccine adjuvants / 42 (6) , 443
None	(2015) Journal of immunology research Adjuvants: Classification, <I> Modus Operandi</I> , and Licensing / 2016 (None) , 1459394
1	(2015) PLoS ONE HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost / 11 (1) , e0145637
None	(2015) Scientific reports Novel platform technology for modular mucosal vaccine that protects against streptococcus / 6 (None) , 39274
4	(2015) Expert review of anti-infective therapy Influenza infection in human host: challenges in making a better influenza vaccine / 14 (4) , 365
3	(2015) International reviews of immunology Anti-Infectious Human Vaccination in Historical Perspective / 35 (3) , 260
8	(2015) Expert review of vaccines New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design / 15 (8) , 1015
8	(2015) Expert review of vaccines Subunit vaccines for the prevention of mucosal infection with <I>Chlamydia trachomatis</I> / 15 (8) , 977
11	(2015) Molecular pharmaceutics Conjugation with an Inulin–Chitosan Adjuvant Markedly Improves the Immunogenicity of <I>Mycobacterium tuberculosis</I> CFP10-TB10.4 Fusion Protein / 13 (11) , 3626
1	(2017) Bioengineering & translational medicine Host‐ and pathogen‐derived adjuvant coatings on protein nanoparticle vaccines / 2 (1) , 120
11	(2015) Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea Vaccine adjuvants: smart components to boost the immune system / 40 (11) , 1238
11	(2015) Human vaccines & immunotherapeutics A novel immunization approach for dengue infection based on conserved T cell epitopes formulated in calcium phosphate nanoparticles / 13 (11) , 2612
None	(2015) BioMed research international The Use of Xanthan Gum as Vaccine Adjuvant: An Evaluation of Immunostimulatory Potential in BALB/c Mice and Cytotoxicity In Vitro / 2017 (None) , 3925024
None	(2015) Annual review of pharmacology and toxicology Innovative Approaches to Improve Anti-Infective Vaccine Efficacy / 57 (None) , 189
5	(2015) Expert review of vaccines Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection / 16 (5) , 403
6	(2017) Expert review of vaccines A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries / 16 (6) , 545
4	(2015) The journal of immunology : official journal of the American Association of Immunologists Near-Infrared 1064 nm Laser Modulates Migratory Dendritic Cells To Augment the Immune Response to Intradermal Influenza Vaccine / 199 (4) , 1319
10	(2017) PLoS ONE Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells / 12 (10) , e0185843
19	(2015) RSC advances Immune response effects of diverse vaccine antigen attachment ways based on the self-made nanoemulsion adjuvant in systemic MRSA infection / 8 (19) , 10425
4	(2015) Human vaccines & immunotherapeutics A comprehensive analysis of Italian web pages mentioning squalene-based influenza vaccine adjuvants reveals a high prevalence of misinformation / 14 (4) , 969
None	(2015) Journal of immunology research Immunoinformatics Approach for Epitope-Based Peptide Vaccine Design and Active Site Prediction against Polyprotein of Emerging Oropouche Virus / 2018 (None) , 6718083
8	(2018) Natural product communications The Sulfated Polysaccharides of Brown Algae and Products of Their Enzymatic Transformation as Potential Vaccine Adjuvants / 13 (8) , 1934578X1801300
None	(2015) Frontiers in immunology Alum/Toll-Like Receptor 7 Adjuvant Enhances the Expansion of Memory B Cell Compartment Within the Draining Lymph Node / 9 (None) , 641
None	(2015) Frontiers in immunology RIG-I-Like Receptors as Novel Targets for Pan-Antivirals and Vaccine Adjuvants Against Emerging and Re-Emerging Viral Infections / 9 (None) , 1379
None	(2015) Frontiers in immunology DAMP-Inducing Adjuvant and PAMP Adjuvants Parallelly Enhance Protective Type-2 and Type-1 Immune Responses to Influenza Split Vaccination / 9 (None) , 2619
None	(2015) Frontiers in immunology Proteomics, Bioinformatics and Structure-Function Antigen Mining For Gonorrhea Vaccines / 9 (None) , 2793
None	(2015) Frontiers in microbiology Prospects on the Use of <I>Schizochytrium</I> sp. to Develop Oral Vaccines / 9 (None) , 2506
3	(2018) Molecular pharmaceutics Enhancing Efficacy and Stability of an Antiheroin Vaccine: Examination of Antinociception, Opioid Binding Profile, and Lethality / 15 (3) , 1062
3	(2015) Journal of medicinal chemistry Lipidated Brartemicin Analogues Are Potent Th1-Stimulating Vaccine Adjuvants / 61 (3) , 1045
2	(2015) Medical microbiology and immunology Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice / 207 (2) , 151
3	(2018) Voprosy virusologi&n.ibreve; CYTOTOXIC PROPERTIES OF TRITERPENE SAPONIN TAUROSID SX1 AND ITS EFFECT ON HUMAN IMMUNODEFICIENCY VIRUS AND INFLUENZA VIRUS INFECTION IN MICE / 63 (3) , 123
6	(2015) Viruses Harnessing T Follicular Helper Cell Responses for HIV Vaccine Development / 10 (6) , 336
2	(2015) Vaccines <I>“Gnothi Seauton”</I> : Leveraging the Host Response to Improve Influenza Virus Vaccine Efficacy / 6 (2) , 23
8	(2018) PLoS ONE Ovalbumin-containing core-shell implants suitable to obtain a delayed IgG1 antibody response in support of a biphasic pulsatile release profile in mice / 13 (8) , e0202961
9	(2015) Infection and immunity Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors / 86 (9) , e00114-18
9	(2015) Expert opinion on drug delivery Microneedle arrays for vaccine delivery: the possibilities, challenges and use of nanoparticles as a combinatorial approach for enhanced vaccine immunogenicity / 15 (9) , 851
10	(2015) Infection and immunity Adjuvant Potential of Poly-α-<SMALL>L</SMALL>-Glutamine from the Cell Wall of <I>Mycobacterium tuberculosis</I> / 86 (10) , e00537-18
4	(2015) 韓國家畜衛生學會誌 Comparison of local reaction at injection site following intramuscular administration with three commercial atrophic rhinitis vaccines in pigs / 41 (4) , 251
10	(2015) International journal of molecular sciences Immunogenicity and Protective Activity of a Chimeric Protein Based on the Domain III of the Tick-Borne Encephalitis Virus E Protein and the OmpF Porin of Yersinia pseudotuberculosis Incorporated int / 19 (10) , 2988
None	(2018) Scientific reports Aluminum salts as an adjuvant for pre-pandemic influenza vaccines: a meta-analysis / 8 (None) , 11460
1	(2015) Virology journal Human β-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigen-specific immunity / 15 (1) , 124
3	(2018) ILAR journal Rational Design and In Vivo Characterization of Vaccine Adjuvants / 59 (3) , 309
None	(2015) International journal of nanomedicine Single-dose Ag85B-ESAT6–loaded poly(lactic- <I>co</I> -glycolic acid) nanoparticles confer protective immunity against tuberculosis / 14 (None) , 3129
6	(2015) Arhiv za farmaciju Adjuvants in vaccines registered for human use / 69 (6) , 406
1	(2015) Parasitology research Plasmodium genomics: an approach for learning about and ending human malaria / 118 (1) , 1
None	(2019) Journal of immunology research New Insights on the Adjuvant Properties of the <I>Leishmania infantum</I> Eukaryotic Initiation Factor / 2019 (None) , 1
None	(2015) Frontiers in immunology ERdj5 in Innate Immune Cells Is a Crucial Factor for the Mucosal Adjuvanticity of Cholera Toxin / 10 (None) , 1249
None	(2015) Frontiers in cellular and infection microbiology The Combination Vaccine Adjuvant System Alum/c-di-AMP Results in Quantitative and Qualitative Enhanced Immune Responses Post Immunization / 9 (None) , 31
2	(2019) Human vaccines & immunotherapeutics Osmolytes in vaccine production, flocculation and storage: a critical review / 15 (2) , 514
None	(2015) Key engineering materials Isolation of Antimicrobial Peptide from Food Protein Hydrolysates: An Overview / 797 (None) , 168
5	(2015) Molecular pharmaceutics Glucan Particles Are a Powerful Adjuvant for the HBsAg, Favoring Antiviral Immunity / 16 (5) , 1971
6	(2019) Infection and immunity Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for / 87 (6) , e00911-18
6	(2019) Drug development and industrial pharmacy Nanostructured cochleates: a multi-layered platform for cellular transportation of therapeutics / 45 (6) , 869
6	(2015) Drug development and industrial pharmacy Subunit-based mucosal vaccine delivery systems for pulmonary delivery - Are they feasible? / 45 (6) , 882
7	(2015) Archives of virology Adjuvant activity of multimolecular complexes based on Glycyrrhiza glabra saponins, lipids, and influenza virus glycoproteins / 164 (7) , 1793
2	(2015) The journal of immunology : official journal of the American Association of Immunologists Protease-Activated Receptor 2 Agonist as Adjuvant: Augmenting Development of Protective Memory CD8 T Cell Responses Induced by Influenza Virosomes / 203 (2) , 441
30	(2015) ACS applied materials & interfaces Conjugation of a Small-Molecule TLR7 Agonist to Silica Nanoshells Enhances Adjuvant Activity / 11 (30) , 26637
16	(2015) Advanced science Lipidic Aminoglycoside Derivatives: A New Class of Immunomodulators Inducing a Potent Innate Immune Stimulation / 6 (16) , 1900288
3	(2015) Vaccines Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection / 7 (3) , 72
6	(2015) Medical microbiology and immunology Immunological evaluation of two novel engineered Plasmodium vivax circumsporozoite proteins formulated with different human-compatible vaccine adjuvants in C57BL/6 mice / 208 (6) , 731
12	(2015) Pharmaceutics Preparation of Squalene Oil-Based Emulsion Adjuvants Employing a Self-Emulsifying Drug Delivery System and Assessment of <I>Mycoplasma hyopneumoniae</I> -Specific Antibody Titers in BALB/c Mice / 11 (12) , 667
None	(2015) Informatics in medicine unlocked Engineering a novel subunit vaccine against SARS-CoV-2 by exploring immunoinformatics approach / 21 (None) , 100478
None	(2015) Frontiers in oncology Personalized Human Papillomavirus Vaccination for Persistence of Immunity for Cervical Cancer Prevention: A Critical Review With Experts' Opinions / 10 (None) , 548
1	(2015) Pharmaceutics Engineered Nanodelivery Systems to Improve DNA Vaccine Technologies / 12 (1) , 30
3	(2020) The journal of immunology : official journal of the American Association of Immunologists Tuning Subunit Vaccines with Novel TLR Triagonist Adjuvants to Generate Protective Immune Responses against <I>Coxiella burnetii</I> / 204 (3) , 611
None	(2015) Frontiers in immunology Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs / 11 (None) , 1100
3	(2015) Advanced therapeutics Potential Zika Vaccine: Encapsulated Nanocomplex Promotes Both T <SUB>H</SUB> 1/T <SUB>H</SUB> 2 Responses in Mice / 3 (3) , 1900197
None	(2020) Molecular immunology Comparative analysis of two HIV-1 multiepitope polypeptides for stimulation of immune responses in BALB/c mice / 119 (None) , 106
3	(2020) The FASEB journal : official publication of the Federation of American Societies for Experimental Biology Laser adjuvant for vaccination / 34 (3) , 3485
5	(2020) Pharmaceutics MERS-CoV Spike Protein Vaccine and Inactivated Influenza Vaccine Formulated with Single Strand RNA Adjuvant Induce T-Cell Activation through Intranasal Immunization in Mice / 12 (5) , 441
3	(2015) Drug delivery and translational research C-di-GMP with influenza vaccine showed enhanced and shifted immune responses in microneedle vaccination in the skin / 10 (3) , 815
2	(2015) Vaccines The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation / 8 (2) , 251
7	(2020) Human vaccines & immunotherapeutics Polysaccharide PCP-I isolated from <I>Poria cocos</I> enhances the immunogenicity and protection of an anthrax protective antigen-based vaccine / 16 (7) , 1699
9	(2015) Journal of cellular physiology <I>Pichia pastoris</I>: A highly successful expression system for optimal synthesis of heterologous proteins / 235 (9) , 5867
10	(2015) Pharmaceutics Evaluation of CpG-ODN-Adjuvanted <I>Toxoplasma gondii</I> Virus-Like Particle Vaccine upon One, Two, and Three Immunizations / 12 (10) , 989
4	(2015) Journal of Alzheimer's disease An Immunomodulatory Therapeutic Vaccine Targeting Oligomeric Amyloid-β / 77 (4) , 1639
12	(2015) Biotechnology journal Biotin Functionalized Self‐Assembled Peptide Nanofiber as an Adjuvant for Immunomodulatory Response / 15 (12) , 2000100
None	(2015) Informatics in medicine unlocked Development of an in silico multi-epitope vaccine against SARS-COV-2 by précised immune-informatics approaches / 27 (None) , 100781
1	(2021) Emerging microbes & infections Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response / 10 (1) , 365
None	(2015) Frontiers in bioengineering and biotechnology Polyphosphazenes as Adjuvants for Animal Vaccines and Other Medical Applications / 9 (None) , 625482
None	(2015) Frontiers in immunology Subunit Vaccines Using TLR Triagonist Combination Adjuvants Provide Protection Against Coxiella burnetii While Minimizing Reactogenic Responses / 12 (None) , 653092
1	(2021) ACS nano Enhancing Immunity with Nanomedicine: Employing Nanoparticles to Harness the Immune System / 15 (1) , 7
2	(2021) PLoS ONE Rational design of multi epitope-based subunit vaccine by exploring MERS-COV proteome: Reverse vaccinology and molecular docking approach / 16 (2) , e0245072
2	(2015) Pathogens Developing a Vaccine to Block West Nile Virus Transmission: In Silico Studies, Molecular Characterization, Expression, and Blocking Activity of Culex pipiens mosGCTL-1 / 10 (2) , 218
2	(2015) Pharmaceutics The Synergistic Effects of Sulfated Lactosyl Archaeol Archaeosomes When Combined with Different Adjuvants in a Murine Model / 13 (2) , 205
3	(2015) Biotechnology and bioengineering High‐ and low‐molecular‐weight chitosan act as adjuvants during single‐dose influenza A virus protein vaccination through distinct mechanisms / 118 (3) , 1224
3	(2021) Vaccines Silicone Oil-Based Nanoadjuvants as Candidates for a New Formulation of Intranasal Vaccines / 9 (3) , 234
3	(2021) Vaccines Immuno-Informatics Analysis of Pakistan-Based HCV Subtype-3a for Chimeric Polypeptide Vaccine Design / 9 (3) , 293
4	(2015) ISPRS international journal of geo-information Analyzing the Research Evolution in Response to COVID-19 / 10 (4) , 237
8	(2015) ChemMedChem : Chemistry Enabling Drug Discovery Design of Trehalose‐Based Amide/Sulfonamide C‐type Lectin Receptor Signaling Compounds / 16 (8) , 1246
2	(2015) mSystems Systems Biology behind Immunoprotection of Both Sheep and Goats after Sungri/96 PPRV Vaccination / 6 (2) , e00820-20
3	(2015) Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Advancements in protein nanoparticle vaccine platforms to combat infectious disease / 13 (3) , None
None	(2015) Veterinary immunology and immunopathology Evaluation of immunogenicity and protection mediated by Lawsonia intracellularis subunit vaccines / 237 (None) , 110256
6	(2015) Protein and peptide letters HIV-1 Accessory Proteins: Which one is Potentially Effective in Diagnosis and Vaccine Development? / 28 (6) , 687
6	(2015) Vaccines Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines / 9 (6) , 563
7	(2015) Infection and immunity Combination Adjuvants Affect the Magnitude of Effector-Like Memory CD8 T Cells and Protection against Listeriosis / 89 (7) , None
None	(2015) Microbial pathogenesis Design, expression, and purification of a multi-epitope vaccine against <I>Helicobacter Pylori</I> based on Melittin as an adjuvant / 157 (None) , 104970
9	(2015) Biology Monophosphoryl Lipid A and Poly I:C Combination Adjuvant Promoted Ovalbumin-Specific Cell Mediated Immunity in Mice Model / 10 (9) , 908
9	(2015) Human vaccines & immunotherapeutics COVID-19 vaccine platforms: Delivering on a promise? / 17 (9) , 2873
10	(2015) Biology Designing a Multi-Epitope Vaccine against Chlamydia trachomatis by Employing Integrated Core Proteomics, Immuno-Informatics and In Silico Approaches / 10 (10) , 997
10	(2015) Vaccines Proteome-Wide Mapping and Reverse Vaccinology Approaches to Design a Multi-Epitope Vaccine against Clostridium perfringens / 9 (10) , 1079
48	(2015) Vaccine Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants / 39 (48) , 7001
17	(2021) Journal of biomolecular structure & dynamics Designing novel epitope-based polyvalent vaccines against herpes simplex virus-1 and 2 exploiting the immunoinformatics approach / 39 (17) , 6585
1	(2021) Journal of genetic engineering & biotechnology PPAR agonists as effective adjuvants for COVID-19 vaccines, by modifying immunogenetics: a review of literature / 19 (1) , 82
12	(2021) Vaccines Potentiation of Recombinant NP and M1-Induced Cellular Immune Responses and Protection by Physical Radiofrequency Adjuvant / 9 (12) , 1382
1	(2015) Journal of biomolecular structure & dynamics Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatics approach / 40 (1) , 14
None	(2022) Computers in biology and medicine Designing of a multi-epitopes-based peptide vaccine against rift valley fever virus and its validation through integrated computational approaches / 141 (None) , 105151